Financial disclosures filed last week revealed that hundreds of thousands of dollars in Eli Lilly shares were purchased on Donald Trump's behalf during the first quarter of 2026, a period when his administration took steps to expand access to the pharmaceutical giant's weight-loss medications.
The ethics filings documented seven separate acquisitions of Eli Lilly stock worth up to $680,000 between January 6 and the end of March. During that same window, multiple federal agencies rolled out initiatives that directly benefited the drugmaker's GLP-1 business. The Center for Medicare and Medicaid Services launched a pilot program expanding coverage of Eli Lilly's obesity treatments, including Zepbound, for Medicare patients. In February, the administration unveiled TrumpRx, a direct-to-consumer drug sales website that initially featured medications from manufacturers who had struck pricing deals with the White House, including Eli Lilly, and directed patients to the company's telemedicine service.
The broader trading activity revealed in the disclosures was substantial. Trump's investment portfolio saw between $220 million and $750 million in cumulative trades across the first quarter, touching major holdings in Apple, Boeing, Goldman Sachs, Meta Platforms, Microsoft, and Nvidia. The Financial Times noted the volume of transactions far exceeded Trump's trading activity during his first year of the second term.
The Trump Organization has stated repeatedly that the president plays no role in his investment decisions. A spokesperson said the portfolio is maintained through fully discretionary accounts managed independently by third-party financial institutions with sole authority over trading. Investment decisions are executed through automated processes, the statement added, with Trump receiving no advance notice of trading activity and providing no input on specific investments.
Trump has cultivated close relationships with major corporate executives since his return to office in January 2025. Just last week, he traveled to China with a delegation that included the chiefs of Apple, Boeing, Goldman Sachs, and Nvidia, among others.
The timing of the Eli Lilly purchases and the favorable government actions drew scrutiny from KFF Health News, which highlighted the transactions. However, Eli Lilly, the Department of Health and Human Services, the White House, and the Trump Organization did not provide comment on the matter.
The disclosures arrive as Trump and his family have faced mounting public attention regarding their expanding wealth from real estate, cryptocurrency investments, and other ventures. This scrutiny comes against a backdrop of continued financial hardship for many Americans, with inflation remaining elevated and fuel costs climbing. When asked last week whether Americans' financial struggles were motivating him to pursue certain foreign policy deals, Trump dismissed the suggestion entirely, saying he does not think about Americans' financial situation and focuses only on preventing Iran from obtaining nuclear weapons.
Author James Rodriguez: "The coincidence between the stock purchases and the policy moves is too neat to ignore, and the automated-account excuse rings hollow when the pattern is this tidy."
Comments